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Abstract (updated)
Background: Metaplastic breast carcinoma (MBC) is a rare subtype of breast
carcinoma less responsive to conventional chemotherapy relative to usual
breast carcinomas such as ductal and lobular subtype. In molecular terms,
MBC usually clusters with triple negative breast cancers (TNBC), but MBCs
portray a worse prognosis in comparison with TNBC. Published studies
investigating MBCs for specific biomarkers of therapy response are rare and
limited by the methodological approaches.
Methods: 297 samples [MBC (n=75), triple-negative breast cancer of nospecial-type (TNBC-NOS, n=106), HER2-positive breast cancers (n=32) and
luminal breast cancers (n=84)] were profiled using direct sequencing analysis
[Illumina MiSeq Next Generation Sequencing (NGS)]. Immunohistochemistry
for PD-L1 (SP142, Spring Bioscience) and PD-1 (NAT105, Ventana) was
performed using automated procedures.
Results: 89% MBCs exhibited triple-negative immunophenotype (ER-/PR/HER2-). The most common mutations in MBCs included TP53 (67%) and
PIK3CA mutations (23%). Other mutations were rare including HRAS mutations
(7%), STK11 (5%), FBXW7, PTEN, c-MET and JAK3 (4%, respectively). PD-L1
expression on cancer cells was detected in significantly higher proportion of
MBCs (46%) than in other molecular subtypes (6% in luminal and HER2+ breast
cancers, respectively and 9% in TNBC-NOS, p<0.001). PD-1 positive tumors
infiltrating lymphocytes (TILs) varied greatly in MBCs (0 to >50/mm2).
Conclusion: Comprehensive profiling of a large cohort of this rare carcinoma
highlighted predominance of TP53 mutations, wild type EGFR gene expression,
a distinct increase in proportion of PD-L1 expression in carcinoma cells, and
PD-1 expression in TILs. The latter properties can be exploited in clinical trials
utilizing immune check point inhibitors.
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Methods

Mutational profiling of metaplastic carcinoma

The study included 297 samples [MBC (n=75), triple-negative
breast cancer of no-special-type (TNBC-NOS, n=106), HER2positive breast cancers (n=32) and luminal (ER+/Her2-) breast
cancers (n=84)]. The samples were profiled using direct
sequencing analysis [Illumina MiSeq Next Generation
Sequencing (NGS)] using formalin-fixed paraffin embedded tissue
blocks. Immunohistochemistry for PD-L1 (SP142, Spring
Bioscience) and PD-1 (EH12.1, Pharmingen) was performed using
automated procedures.

Results (updated)
Mean age of patients: 57 years (range, 35-93 years).
Histology: MBCs exhibited various morphologic features
including squamous, myoepithelial, spindle, and rhabdoid
morphology with heterologous elements: bone (n=3) and
cartilage (n=22 cases).
ER, PR and HER2 status were available for 71 patients; 63 cases
(89%) of MBCs exhibited triple-negative phenotype; the
remaining 8 cases (11%) were ER/or PR positive (7 cases) and
HER2 positive (1 case).

PD-1 and PD-L1 expression in metaplastic carcinoma

Table 2. The stratification of MBCs into 4 types (5) on the basis of
PD-L1 and TILs status; The proposed stratification is a framework
to tailored (tailor) immunotherapy against tumor
microenvironment (TME);
PD-1 positive tumors infiltrating lymphocytes (TILs) varied greatly
in MBCs (0 to 400/mm2, mean: 67.3). No significant association
was found between the number of TILs and PD-L1 status
(p=0.209).

Overall PD-L1 positivity among 75 metaplastic
breast carcinomas was 46%; highest of all types.
Figure 1

Background

Metaplastic breast carcinoma (MBC) encompasses a group
of mammary neoplasms characterized by differentiation of
the neoplastic epithelium into squamous or mesenchymal
cells (1). It is less responsive to conventional chemotherapy
compared to the usual ductal and lobular breast
carcinomas (2). In molecular terms, MBC usually clusters
with triple negative (ER-/PR-/ Her2-) breast cancer (TNBC),
but MBCs portray a worse prognosis in comparison with
TNBC. Published studies investigating MBCs for specific
biomarkers of therapy response are rare and limited by the
methodological approaches (3, 4).
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Figure 2

72 MBCs were tested by NGS of which 57 cases had
interpretable results. Mutations were detected in 16 out of 45
tested genes affecting 48 out 57 metaplastic carcinomas (84%).
TP53 mutation was the most frequent mutation (32/57, 56%).
In 20 cases, TP53 was the sole mutation detected in the tumor
tissue while in the remaining 12 cases other mutations cooccurred. PIK3CA mutation was the second most common
mutation (13/72, 23%) while HRAS mutations was detected in 4
cases (7%), STK11 in 3 cases (5%), FBXW7, PTEN, c-MET and
JAK3 in two cases, respectively (4%). Single cases harbored
mutations of AKT1, APC, BRAF, RET, c-KIT, MLH1, RET, and
SMAD4 genes. None of the cases harbored EGFR mutation.

Conclusions
Metaplastic carcinomas are characterized by
increased PD-L1 expression in carcinoma cells, and
PD-1 expression in TILs, which can be exploited in
clinical trials utilizing immune check point
inhibitors in this hard-to-treat subtype of breast
cancer.
Comprehensive mutational profiling of MBC
highlighted predominance of TP53 and PIK3CA
mutations and a wild type EGFR gene expression.

References
1.
2.
3.

4.

Figures 1A-D, 2A-D. Despite various morphologic appearances (A, C) of

Table 1. PD-L1 expression was significantly higher in metaplastic carcinomas in
comparison with other breast cancer subtypes (46% vs. 6-9%, p<0.001).

metaplastic carcinomas, strong PD-L1 overexpression (B, D) was observed in
nearly 50% of the cases.

5.

Reis –Filho JS et al. Metaplastic carcinoma. In WHO Classification of tumours of the breast. Lakhani SR,
Ellis IO, Schnitt SJ, Tan PH and van der Vijver MJ (Eds). IARC Press Lyon 2012.
Abouharb S, Moulder S. Metaplastic Breast Cancer: Clinical Overview and Molecular Aberrations for
Potential Targeted Therapy. Curr Oncol Rep 2015;17:10.
Elizabeth McKinnon E, Xiao P. Metaplastic Carcinoma of the Breast. Arch Pathol Lab Med 2015;139:819–
822.
Zhang Y, Toy KA, Kleer CG. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells
andepithelial to mesenchymal transition. Mod Pathol 2012;25:178-84.
Smyth MJ et al. Combination cancer immunotherapyies tailored to the tumour microenvironment .
Nature Rev Clin Oncol 2015 doi: 10.1038/nrclinonc.2015.209. [Epub ahead of print] Review.

